TWI864749B - 化合物及其用途 - Google Patents
化合物及其用途 Download PDFInfo
- Publication number
- TWI864749B TWI864749B TW112117604A TW112117604A TWI864749B TW I864749 B TWI864749 B TW I864749B TW 112117604 A TW112117604 A TW 112117604A TW 112117604 A TW112117604 A TW 112117604A TW I864749 B TWI864749 B TW I864749B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- group
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340927P | 2022-05-11 | 2022-05-11 | |
| US63/340,927 | 2022-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202411228A TW202411228A (zh) | 2024-03-16 |
| TWI864749B true TWI864749B (zh) | 2024-12-01 |
Family
ID=86732694
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112117604A TWI864749B (zh) | 2022-05-11 | 2023-05-11 | 化合物及其用途 |
| TW113141340A TW202506693A (zh) | 2022-05-11 | 2023-05-11 | 化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113141340A TW202506693A (zh) | 2022-05-11 | 2023-05-11 | 化合物及其用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12139487B2 (enExample) |
| EP (1) | EP4522280A1 (enExample) |
| JP (2) | JP7531656B2 (enExample) |
| KR (1) | KR20250024923A (enExample) |
| CN (1) | CN119677738A (enExample) |
| AR (1) | AR129299A1 (enExample) |
| AU (1) | AU2023270055A1 (enExample) |
| CA (1) | CA3252955A1 (enExample) |
| CL (1) | CL2024003450A1 (enExample) |
| CO (1) | CO2024015229A2 (enExample) |
| DO (1) | DOP2024000231A (enExample) |
| IL (1) | IL316531A (enExample) |
| MX (1) | MX2024013838A (enExample) |
| PE (1) | PE20250261A1 (enExample) |
| TW (2) | TWI864749B (enExample) |
| WO (1) | WO2023220219A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025008060A1 (en) * | 2023-07-05 | 2025-01-09 | Janssen Pharmaceutica Nv | 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers |
| WO2025099307A1 (en) * | 2023-11-10 | 2025-05-15 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2025237242A1 (zh) * | 2024-05-14 | 2025-11-20 | 上海和誉生物医药科技有限公司 | 一种smarca2抑制剂及其应用 |
| CN118930537B (zh) * | 2024-07-23 | 2025-05-13 | 上海信诺维生物医药有限公司 | 一种抑制brm的化合物 |
| CN118930561B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种稠环化合物 |
| CN118908980B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种多环化合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021155320A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155316A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| TW202136252A (zh) * | 2020-01-29 | 2021-10-01 | 美商福宏治療公司 | 化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| MA40551A (fr) | 2014-08-01 | 2021-04-07 | Nuevolution As | Composés actifs envers des bromodomaines |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| EP4244213A4 (en) * | 2020-11-10 | 2024-11-20 | Foghorn Therapeutics Inc. | COMPOUNDS AND USES THEREOF |
-
2023
- 2023-05-11 US US18/315,526 patent/US12139487B2/en active Active
- 2023-05-11 PE PE2024002469A patent/PE20250261A1/es unknown
- 2023-05-11 CA CA3252955A patent/CA3252955A1/en active Pending
- 2023-05-11 WO PCT/US2023/021793 patent/WO2023220219A1/en not_active Ceased
- 2023-05-11 IL IL316531A patent/IL316531A/en unknown
- 2023-05-11 CN CN202380053231.6A patent/CN119677738A/zh active Pending
- 2023-05-11 KR KR1020247041093A patent/KR20250024923A/ko active Pending
- 2023-05-11 TW TW112117604A patent/TWI864749B/zh active
- 2023-05-11 JP JP2023078608A patent/JP7531656B2/ja active Active
- 2023-05-11 AU AU2023270055A patent/AU2023270055A1/en active Pending
- 2023-05-11 EP EP23729898.9A patent/EP4522280A1/en active Pending
- 2023-05-11 AR ARP230101168A patent/AR129299A1/es unknown
- 2023-05-11 TW TW113141340A patent/TW202506693A/zh unknown
-
2024
- 2024-07-30 JP JP2024122975A patent/JP2024156779A/ja active Pending
- 2024-10-25 US US18/926,578 patent/US20250066354A1/en active Pending
- 2024-11-07 CO CONC2024/0015229A patent/CO2024015229A2/es unknown
- 2024-11-08 MX MX2024013838A patent/MX2024013838A/es unknown
- 2024-11-11 CL CL2024003450A patent/CL2024003450A1/es unknown
- 2024-11-11 DO DO2024000231A patent/DOP2024000231A/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021155320A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155316A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| TW202136252A (zh) * | 2020-01-29 | 2021-10-01 | 美商福宏治療公司 | 化合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023168298A (ja) | 2023-11-24 |
| AR129299A1 (es) | 2024-08-07 |
| KR20250024923A (ko) | 2025-02-20 |
| JP2024156779A (ja) | 2024-11-06 |
| WO2023220219A1 (en) | 2023-11-16 |
| PE20250261A1 (es) | 2025-01-29 |
| TW202411228A (zh) | 2024-03-16 |
| IL316531A (en) | 2024-12-01 |
| MX2024013838A (es) | 2025-03-07 |
| EP4522280A1 (en) | 2025-03-19 |
| AU2023270055A1 (en) | 2024-11-28 |
| DOP2024000231A (es) | 2024-12-15 |
| CN119677738A (zh) | 2025-03-21 |
| CL2024003450A1 (es) | 2025-03-14 |
| TW202506693A (zh) | 2025-02-16 |
| US20230365560A1 (en) | 2023-11-16 |
| CA3252955A1 (en) | 2023-11-16 |
| JP7531656B2 (ja) | 2024-08-09 |
| CO2024015229A2 (es) | 2025-03-06 |
| US20250066354A1 (en) | 2025-02-27 |
| US12139487B2 (en) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12441726B2 (en) | Compounds and uses thereof | |
| AU2021378949B2 (en) | Compounds and uses thereof | |
| TWI864749B (zh) | 化合物及其用途 | |
| JP7600396B2 (ja) | 化合物及びその使用 | |
| IL285177B1 (en) | Compounds and their use | |
| US20230150974A1 (en) | Compounds and uses thereof | |
| CA3166404A1 (en) | A bifunctional molecule comprising an active compound,a linker and a degradation moiety, and its use to treat disorders associated with baf complex function | |
| AU2023270000A1 (en) | Pyrazine derivatives and uses thereof | |
| CA3252914A1 (en) | PYRAZINE DERIVATIVES AND THEIR USES | |
| EA049084B1 (ru) | Соединения и их применение |